Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE long-term seladelpar safety study in PBC
2020-005198-29Phase 3Active
- Sponsor
- CymaBay Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by CymaBay Therapeutics. Primary endpoints: Treatment-emergent adverse events and Clinical laboratory safety parameters. Started Feb 2021; status: active.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2020-005198-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005198-29.